Profiling of Target Molecules for Immunotherapy in Mesenchymal Tumors

The use of anti-human signal molecules monoclonal antibodies (mAbs) for malignant tumors therapy has achieved considerable success in recent years. Antibody drug conjugates are powerful new clinical treatment options for lymphomas and solid tumors, and immunomodulatory antibodies have also recently achieved remarkable clinical success. The development of therapeutic antibodies requires a deep understanding of malignant tumor serology, protein-engineering techniques, mechanisms of action and resistance, and the interplay between the immune system and tumorigenesis. This review outlines the fundamental strategies, which are required to establish antibody therapies for patients with mesenchymal tumors through iterative approaches to target and antibody selection, extending from preclinical studies to human trials.